CD274 and non-small cell lung carcinoma: Based on the clinical trial evaluating SHR-1316, a PD-L1 monoclonal antibody, or placebo combined with chemotherapy for preoperative treatment of resectable Stage II-III non-small cell lung cancer (a randomized, double-blind, multi-center Phase IB/III trial, NCT04316364), Arraystar Small RNA microarray (Aksomics, Shanghai) analysis was performed on pre-treatment LUAD samples from 3 cases of progressive disease (PD) and 3 cases of partial response (PR), according to RECIST v1.1 criteria (Fig. 1A).